Carmen Ghilardi
0000-0002-3036-8557
Publication & Citation Trends
Most Cited Works
Publications
107 total
PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer PDF
Cited by 41
OpenAlex
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases PDF
Cited by 30
OpenAlex
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status PDF
Cited by 59
OpenAlex
A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing PDF
Cited by 58
OpenAlex
Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists
Cited by 28
OpenAlex
Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
Cited by 132
OpenAlex
Thrombospondin‐1 is part of a Slug‐independent motility and metastatic program in cutaneous melanoma, in association with <scp>VEGFR</scp>‐1 and <scp>FGF</scp>‐2 PDF
Cited by 52
OpenAlex
Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle PDF
Cited by 46
OpenAlex
Research Topics
Ovarian cancer diagnosis and treatment
(38)
PARP inhibition in cancer therapy
(31)
Cancer, Hypoxia, and Metabolism
(24)
Cancer, Lipids, and Metabolism
(19)
Cancer Genomics and Diagnostics
(12)
Frequent Co-Authors
Affiliations
Mario Negri Institute for Pharmacological Research
Atlantia (Italy)
Cancer Research UK Scotland Institute
Istituti di Ricovero e Cura a Carattere Scientifico